Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD

Alexander G. Mathioudakis, Andras Bikov, Philip Foden, Lies Lahousse, Guy Brusselle, Dave Singh, Jørgen Vestbo
European Respiratory Journal 2020 55: 1902119; DOI: 10.1183/13993003.02119-2019
Alexander G. Mathioudakis
1Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK
2North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander G. Mathioudakis
Andras Bikov
1Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK
2North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Foden
3Dept of Medical Statistics, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lies Lahousse
4Dept of Bioanalysis, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lies Lahousse
Guy Brusselle
5Depts of Epidemiology and Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
6Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy Brusselle
Dave Singh
1Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK
2North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
7Medicines Evaluation Unit, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jørgen Vestbo
1Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK
2North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jørgen Vestbo
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There is an emerging role for blood eosinophil count (EOS) as a biomarker to guide inhaled corticosteroid (ICS) therapy in COPD. Since ICS administration could influence EOS, we hypothesised that change in EOS following treatment with ICS may predict outcomes of long-term therapy.

In a post hoc analysis of ISOLDE, a 3-year, double-blind trial comparing 500 µg fluticasone propionate twice daily with placebo in 751 patients with moderate-to-severe COPD, we evaluated whether the initial changes in EOS during ICS treatment were predictive of ICS treatment response.

EOS change within 1 year after the introduction of ICS was strongly predictive of treatment response. A suppressed EOS was associated with treatment effect. Characteristically, in patients with EOS suppression of ≥200 cells·μL−1, ICS use was associated with a decelerated rate of decline of forced expiratory volume in 1 s (FEV1), by 32 mL·year−1, and a 30% reduction in the exacerbation rate. In contrast, in patients experiencing an increase in EOS of ≥200 cells·μL−1, ICS use was associated with an accelerated rate of decline of FEV1, by 37 mL·year−1 and an 80% increase in the exacerbation rate (p<0.0001). EOS change was not predictive of clinical response with regards to health status evaluated using the St George's Respiratory Questionnaire.

These findings suggest that EOS change after ICS administration may predict clinical response to ICS therapy in patients with moderate-to-severe COPD at risk of exacerbations. ICS administration may be associated with more frequent exacerbations and an accelerated lung function decline in the 20% of patients in whom EOS increases after the administration of ICS. These hypothesis-generating observations will need validation in prospectively designed studies.

The ISOLDE trial was conducted before the ICJME recommended a prospective registration of RCT protocols.

Abstract

Blood eosinophil change in response to ICS may predict long-term response to ICS in COPD. A rise in eosinophils was observed in 20% of participants in ISOLDE and was associated with lack of clinical benefit and a potential risk of harm. http://bit.ly/3bPKLnD

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Author contributions: A.G. Mathioudakis and J. Vestbo contributed to the conception and design of the study. A.G. Mathioudakis conducted data analysis and drafted the manuscript with input from all authors. P. Foden provided statistical expertise. All authors contributed to data interpretation, discussion and critical revision of the paper for intellectual content.

  • Data availability: Data ownership lies with GlaxoSmithKline. Data sharing is possible via Clinical Study Data Request platform (www.clinicalstudydatarequest.com), after submission of a research proposal, which is reviewed by an independent research panel.

  • Conflict of interest: A.G. Mathioudakis reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: A. Bikov has nothing to disclose.

  • Conflict of interest: P. Foden has nothing to disclose.

  • Conflict of interest: L. Lahousse reports grants from AstraZeneca, grants from Chiesi, personal fees from Boehringer Ingelheim, personal fees from Novartis, outside the submitted work.

  • Conflict of interest: G. Brusselle reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Teva, personal fees from Sanofi, outside the submitted work.

  • Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, grants and personal fees from GlaxoSmithKline, grants and personal fees from Glenmark, grants and personal fees from Menarini, grants and personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Peptinnovate, grants and personal fees from Pfizer, grants and personal fees from Pulmatrix, grants and personal fees from Therevance, grants and personal fees from Verona, outside the submitted work.

  • Conflict of interest: J. Vestbo reports personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work.

  • Support statement: A.G. Mathioudakis is supported by an Academic Clinical Fellowship in Respiratory Medicine from the National Institute for Health Research (NIHR, UK). A.G. Mathioudakis, D. Singh, A. Bikov and J. Vestbo are supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received June 30, 2019.
  • Accepted February 17, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 5 Table of Contents
European Respiratory Journal: 55 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Alexander G. Mathioudakis, Andras Bikov, Philip Foden, Lies Lahousse, Guy Brusselle, Dave Singh, Jørgen Vestbo
European Respiratory Journal May 2020, 55 (5) 1902119; DOI: 10.1183/13993003.02119-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Alexander G. Mathioudakis, Andras Bikov, Philip Foden, Lies Lahousse, Guy Brusselle, Dave Singh, Jørgen Vestbo
European Respiratory Journal May 2020, 55 (5) 1902119; DOI: 10.1183/13993003.02119-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • OSTEOPOROSIS AND FRAGILITY FRACTURES IN ASTHMA
  • Rifampicin-resistant TB cure rates and severe ototoxicity prevention
  • Identifying asthma phenotypes based on extrapulmonary traits
Show more Original Articles

COPD

  • Metered cryospray for patients with chronic bronchitis in COPD
  • Granularity of SERPINA1 alleles by DNA sequencing
  • Day-to-day variability of forced oscillatory mechanics in COPD
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society